The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 ...
Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval ...
The Brighterside of News on MSN3h
Critical link between protein and ALS disease offers new hopeScientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...
Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...
The research, led by the ALS Association in collaboration with several leading ALS clinicians, examined Medicare claims made from 2011 to 2021 and found that the average time for ...
It can take twice as long for people to receive an ALS diagnosis if they are seen in a general neurology clinic compared to a specialist clinic, ...
FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS ...
The slaying has unleashed a wave of public feeling — exasperation, anger, resentment, helplessness from Americans sharing ...
Words written on ammunition at the shooting scene — “delay,” “deny” and “depose” — echo those used to describe how insurers dodge claim payouts.
He is remembered as a founding member of the Westerleigh Folk Festival, a dedicated father and friend, and a medical aid in ...
The rNLS8 model is a twofold transgenic model in which human TDP-43 expression is suppressed by doxycycline (Dox) and has a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback